Latest financial information on our operations and affecting developments

Financial News

Notice of convening annual regular assembly of Bosnalijek joint stock company
Pursuant to Article 230, paragraph (1) of Company Law (Official Gazette of FB&H, No. 81/15) and Article 48, paragraph (1) and (2) of valid Bosnalijek d.d. Statute (consolidated text No: 2830/2017 of 18.09.2017), and based on the Supervisory Board's Decision on Convening Annual Regular Assembly No: 1614/19 of 29.05.2019, we hereby announce:
Bosnalijek achieves Record Turnover of 107 million BAM in Foreign Markets
Bosnalijek recorded great business results in 2017, further underlining its reputation as the leading pharmaceutical company in Bosnia and Herzegovina (BiH). This is confirmed by achieved sales revenue to the amount of 153 million BAM, which represents an increase of 17 million BAM or 13 per cent in comparison to 2016. Profit before tax was 13 million BAM, an increase of 12 per cent compared to profit generated in 2016.
In detail
Continuous Growth: Bosnalijek Revenue increases by 35 per cent in 2017
During the first ten months of 2017, Bosnalijek revenue increased by 35 per cent compared to the same period in the previous year.
In detail
Previous Announcements
Notification - Proposals of candidates for members of Bosnalijek d.d. Su ... Notice of Reconvened Annual General Assembly of Bosnalijek d.d. Annual General Assembly of Bosnalijek d.d. - NOTIFICATIONS Excellent Sales Results on the Russian Market Recapitalisation enabled New Investment in and the further Development o ... Bosnalijek saw Revenue and Profit Increase in 2016 Announcement of the Fifth (V) Issuance of Shares through a Closed Offeri ... Report on a Development that significantly affects the Financial Operati ... Bosnalijek makes Record Profit Report from the Voting Committee – 23 June 2014 Bosnalijek makes a Net Profit of 2 Million BAM
juni 24. 2019 |
BSNLR - Bosnalijek d.d. Sarajevo: 12,47 3,89%